ArticleNature communications2019
Multifunctional cationic nanosystems for nucleic acid therapy of thoracic aortic dissection.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 51 citations in OpenAlex.
- Pollen-Based Artificial Enzyme With Efficient Biocatalysis and Immune-Priming to Prevent Primary and Secondary Wound Infection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Beyond Uncertainty: Establishing the Oda Strategy for the Treatment of Acute Aortic Dissection.Journal of clinical medicine · 2025Review
- Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.International journal of molecular sciences · 2024Review
- Hydrophobic aerogel-modified hemostatic gauze with thermal management performance.Bioactive materials · 2023Article
- Article
- Macrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury.Bioactive materials · 2022Article
- Using Molecular Targets to Predict and Treat Aortic Aneurysms.Reviews in cardiovascular medicine · 2022Review
- Biomedical polymers: synthesis, properties, and applications.Science China. Chemistry · 2022Review
- A novel approach to identify the mechanism of miR-145-5p toxicity to podocytes based on the essential genes targeting analysis.Molecular therapy. Nucleic acids · 2021Article
- Reversible Treatment of Pressure Overload-Induced Left Ventricular Hypertrophy throughAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Non-coding RNAs in aortic dissection: From biomarkers to therapeutic targets.Journal of cellular and molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic aortic dissection (TAD) is an aggressive vascular disease that requires early diagnosis and effective treatment. However, due to the particular vascular structure and narrowness of lesion location, there are no effective drug delivery systems for the therapy of TAD. Here, we report a multifunctional delivery nanosystem (TP-Gd/miRNA-ColIV) composed of gadolinium-chelated tannic acid (TA), low-toxic cationic PGEA (ethanolamine-aminated poly(glycidyl methacrylate)) and type IV collagen targeted peptide (ColIV) for targeted nucleic acid therapy, early diagnosis and noninvasive monitoring of TAD. Such targeted therapy with miR-145 exhibits impressive performances in stabilizing the vascular structures and preventing the deterioration of TAD. After the treatment with TP-Gd/miR-145-ColIV, nearly no dissection occurs in the thoracic aortic arches of the mice with TAD model. Moreover, TP-Gd/miRNA-ColIV also demonstrates good magnetic resonance imaging (MRI) ability and can be used to noninvasively monitor the development conditions of TAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.